Released Nov 8, 2017, after the close
10-Q filed Nov 8, 2017, 39 days after period end · 0001144204-17-057290
Q3 2017 · 10-Q
Revenue$7.53M$7.53M +61.2% vs Q3 2016+18.4% vs Q2 2017
Net Income-$11.44M-$11.44M N/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$0.09-$0.09 N/M vs Q3 2016N/M vs Q2 2017
Gross Profit$1,460,000+246.0%
Operating Income-$7,765,000N/M
Operating Cash Flowderived-$10,539,000N/M
Free Cash Flowderived-$10,677,000N/M
Margins · derived
Gross margin19.4%+10.4 pt vs Q3 2016
Operating margin-103.2%+39.2 pt vs Q3 2016
Net margin-152.0%+4.1 pt vs Q3 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2017 | Q3 2016 | Q3 2015 | Q3 2014 |
|---|---|---|---|---|
| Revenue | $7.53M | $4.67M | $1.34M | $2.40M |
| Net Income | -$11.44M | -$7.29M | -$3.82M | -$8.01M |
| EPS Diluted | -$0.09 | -$0.07 | -$0.04 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR